COX-2 Class Is TARGET Of Critical Lancet Editorial
Executive Summary
The TARGET study's mixed results on Novartis' Prexige prompted an editorial critique of the entire COX-2 inhibitor class of drugs
You may also be interested in...
Drug Development Needs “Extreme Makeover,” Researcher Topol Says
The pharmaceutical business needs an "extreme makeover," Cleveland Clinic cardiologist Eric Topol, MD, maintained during the 2004 Medical Innovation Summit in Cleveland
Drug Development Needs “Extreme Makeover,” Researcher Topol Says
The pharmaceutical business needs an "extreme makeover," Cleveland Clinic cardiologist Eric Topol, MD, maintained during the 2004 Medical Innovation Summit in Cleveland
Prexige TARGET Study: Not Quite A Bull’s-Eye For Novartis
Novartis' TARGET study found that the COX-2 inhibitor Prexige has approximately one-third the rate of gastrointestinal side effects compared to non-steroidal anti-inflammatory drugs